![]() Efficacy results for pts with pMMR disease and all-comer pts are shown in the table. Median time from randomization to data cutoff (Mar 1, 2022) was 34.3 (range, 25.1−43.0) mo. Resultsġ55 pts from the East Asian countries of Japan, Taiwan, and South Korea were enrolled (len + pembro, n = 77 TPC, n = 78) 134 pts had pMMR disease (len + pembro, n = 66 TPC, n = 68). Primary endpoints were PFS per RECIST v1.1 by BICR and OS. Randomization was first stratified by MMR status (pMMR or dMMR), then pts with pMMR disease were further stratified by ECOG PS, geographic region, and history of pelvic radiation. Pts were randomized 1:1 to len 20 mg PO QD + pembro 200 mg IV Q3W (up to 35 cycles) or TPC (doxorubicin 60 mg/m2 IV Q3W or paclitaxel 80 mg/m2 IV QW ). MethodsĮligible pts were women ≥18 y with histologically confirmed advanced, recurrent, or metastatic EC with PD after 1 prior platinum-based chemo regimen (2 if 1 given in neoadjuvant or adjuvant setting) and ECOG PS 0-1. We present outcomes for the Asian subgroup from Study 309/KEYNOTE-775 at the time of final prespecified efficacy analysis. In the global phase 3 Study 309/KEYNOTE-775 (NCT03517449), lenvatinib (len) + pembrolizumab (pembro) significantly improved PFS and OS vs treatment of physician’s choice chemotherapy (TPC) in patients (pts) with previously treated advanced endometrial cancer (EC).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |